Citadel Advisors’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-448,691
| Closed | -$1.84M | – | 14850 |
|
|
2022
Q1 | $1.84M | Buy |
448,691
+395,190
| +739% | +$1.43M | ﹤0.01% | 6269 |
|
|
2021
Q4 | $191K | Sell |
53,501
-35,753
| -40% | -$125K | ﹤0.01% | 11915 |
|
|
2021
Q3 | $325K | Buy |
89,254
+2,711
| +3% | +$11K | ﹤0.01% | 10893 |
|
|
2021
Q2 | $377K | Sell |
86,543
-33,997
| -28% | -$138K | ﹤0.01% | 10718 |
|
|
2021
Q1 | $495K | Sell |
120,540
-169,938
| -59% | -$736K | ﹤0.01% | 9699 |
|
|
2020
Q4 | $1.16M | Buy |
290,478
+208,892
| +256% | +$676K | ﹤0.01% | 6492 |
|
|
2020
Q3 | $221K | Sell |
81,586
-160,539
| -66% | -$444K | ﹤0.01% | 8650 |
|
|
2020
Q2 | $666K | Sell |
242,125
-395,924
| -62% | -$1.1M | ﹤0.01% | 6558 |
|
|
2020
Q1 | $1.5M | Buy |
638,049
+267,535
| +72% | +$910K | ﹤0.01% | 4613 |
|
|
2019
Q4 | $1.74M | Buy |
370,514
+306,839
| +482% | +$1.26M | ﹤0.01% | 4642 |
|
|
2019
Q3 | $213K | Sell |
63,675
-98,221
| -61% | -$323K | ﹤0.01% | 8074 |
|
|
2019
Q2 | $533K | Sell |
161,896
-1,586
| -1% | -$4.59K | ﹤0.01% | 6732 |
|
|
2019
Q1 | $495K | Buy |
163,482
+66,142
| +68% | +$214K | ﹤0.01% | 6802 |
|
|
2018
Q4 | $265K | Buy |
97,340
+65,845
| +209% | +$217K | ﹤0.01% | 7473 |
|
|
2018
Q3 | $106K | Sell |
31,495
-6,225
| -17% | -$19.2K | ﹤0.01% | 8550 |
|
|
2018
Q2 | $97K | Buy |
+37,720
| New | +$93.9K | ﹤0.01% | 8256 |
|
|
2018
Q1 | – | Sell |
-13,498
| Closed | -$27K | – | 8984 |
|
|
2017
Q4 | $27K | Sell |
13,498
-101,350
| -88% | -$221K | ﹤0.01% | 7786 |
|
|
2017
Q3 | $372K | Sell |
114,848
-16,044
| -12% | -$49.5K | ﹤0.01% | 5733 |
|
|
2017
Q2 | $422K | Buy |
130,892
+47,010
| +56% | +$133K | ﹤0.01% | 5365 |
|
|
2017
Q1 | $238K | Buy |
83,882
+65,262
| +350% | +$157K | ﹤0.01% | 6241 |
|
|
2016
Q4 | $43K | Sell |
18,620
-3,354
| -15% | -$6.39K | ﹤0.01% | 6903 |
|
|
2016
Q3 | $37K | Sell |
21,974
-9,596
| -30% | -$11.8K | ﹤0.01% | 6918 |
|
|
2016
Q2 | $33K | Buy |
+31,570
| New | +$30.5K | ﹤0.01% | 6506 |
|
|
2016
Q1 | – | Sell |
-7,567
| Closed | -$9K | – | 8373 |
|
|
2015
Q4 | $9K | Sell |
7,567
-311,086
| -98% | -$433K | ﹤0.01% | 8315 |
|
|
2015
Q3 | $542K | Buy |
318,653
+313,159
| +5,700% | +$614K | ﹤0.01% | 4703 |
|
|
2015
Q2 | $11K | Sell |
5,494
-40,718
| -88% | -$98.7K | ﹤0.01% | 8387 |
|
|
2015
Q1 | $125K | Buy |
46,212
+308
| +0.7% | +$781 | ﹤0.01% | 6662 |
|
|
2014
Q4 | $118K | Sell |
45,904
-247,134
| -84% | -$555K | ﹤0.01% | 6508 |
|
|
2014
Q3 | $537K | Buy |
293,038
+132,451
| +82% | +$289K | ﹤0.01% | 4525 |
|
|
2014
Q2 | $429K | Buy |
160,587
+118,024
| +277% | +$355K | ﹤0.01% | 4605 |
|
|
2014
Q1 | $149K | Sell |
42,563
-46,278
| -52% | -$205K | ﹤0.01% | 5805 |
|
|
2013
Q4 | $398K | Buy |
88,841
+75,957
| +590% | +$309K | ﹤0.01% | 4273 |
|
|
2013
Q3 | $52K | Sell |
12,884
-44,744
| -78% | -$195K | ﹤0.01% | 5779 |
|
|
2013
Q2 | $240K | Buy |
+57,628
| New | +$223K | ﹤0.01% | 4503 |
|
Other funds holding ATRS
Citadel Advisors's ATRS Position: Q2 2022 in Review
Citadel Advisors sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 448,691 shares — an estimated $1.84M sold.
Citadel Advisors first reported a position in ATRS in Q2 2013 and held it in 34 quarters. The position peaked at $1.84M in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Citadel Advisors reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Citadel Advisors sold 448,691 Antares Pharma, Inc. shares in Q2 2022, an estimated $1.84M.
- Citadel Advisors first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 34 quarters.
- Citadel Advisors's Antares Pharma, Inc. position peaked at $1.84M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.